Online fast-fashion retailer SHEIN and its newer rival Temu are in a race to win shoppers' attention for their inexpensive China-made goods.
“I think as Temu gets a higher profile, there will just be more and more lawsuits. Including IP, but probably not just IP. I'm sure there will be data-related things as well,” US and China tech analyst Rui Ma said.
three people with knowledge of its plans told Reuters. SHEIN said it does not currently have plans for an IPO and declined to comment further. Social media influencers on TikTok often mention SHEIN in posts about Temu, comparing the companies and their merchandise. The now-deleted @SHEIN_DC, @SHEIN_USA_, and @SHEIN_NYC pages were created in September and displayed SHEIN's logo and marketing material on their bio pages, according to screenshots provided with SHEIN's complaint."Temu has also attempted to impersonate the SHEIN brand and trick consumers into believing Temu is associated with that brand," the lawsuit alleges.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
The World’s Richest People Lost $10 Trillion in 2022, a New Report SaysEven the super-rich aren't immune to financial setbacks. According to a new report, the world's wealthiest individuals lost a collective $10 trillion last year—the biggest decline since 2010.
Baca lebih lajut »
An expert shares 5 things you need to get more organized — starting at $10Getting a head start on your spring home refresh is easy with this list 🧼✨
Baca lebih lajut »
China's SHEIN set to raise $2 billion, eyes US IPO later this year -sourcesChinese online fashion retailer SHEIN is set to raise around $2 billion in a new funding round this month and is aiming for a U.S. listing in the second half of this year, three people with knowledge of its plans told Reuters.
Baca lebih lajut »
China's SHEIN set to raise $2 bln, eyes US IPO later this year -sourcesChinese online fashion retailer SHEIN is set to raise around $2 billion in a new funding round this month and is aiming for a U.S. listing in the second half of this year, three people with knowledge of its plans told Reuters.
Baca lebih lajut »
Shares of this under-the-radar cell therapy stock are set to double, says BairdBaird initiated coverage of bluebird bio with an outperform rating and $10 price target, which implies 104% upside from Monday's close.
Baca lebih lajut »